The companies on our list have seen sales surge followed by its stock price
SmallCapPower | September 22, 2016: Revenue generation is key to the survival of any business because without it a company would die. When revenues are increasing it means that management and its teams are developing new revenue streams or expanding current streams, which ultimately leads to a more profitable and therefore more valuable company. The companies on our list today have seen substantial increases in their revenues over the last 12 months, and it’s been reflected in the stock price this year.
TSO3 Inc. (TSE:TOS) – $3.20
Biotechnology & Medical Research
TSO3 Inc. is a Canada-based company engaged in the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment. Its products are used in the sterilization departments of hospital and other medical facilities. The Company’s STERIZONE VP4 Sterilizer is a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide (H2O2) and ozone (O3) as its sterilants. The STERIZONE VP4 terminally sterilizes multiple channels in a single device.
- Market Cap: $291.92 (M)
- Revenue LTM: $9.275 (M)
- Revenue LTM-1: $0.45(M)
- 1 Year Revenue Growth: 1941%
- YTD Price Change: 43.5%
Aphria Inc. (CVE:APH) – $3.15
Medical Marijuana Producer
Aphria Inc., formerly Black Sparrow Capital Corp., is a Canada-based company, which is engaged in producing and selling medical marijuana through retail sales and wholesale channels. The Company’s retail sales are primarily sold through the Company’s online store, as well as telephone orders. Its wholesale shipments are sold to other Medical Purposes Regulations (MMPR) Licensed Producers. It offers medical cannabis of various strains, including Kusawa, Tamaracouta, Panache, Churchill and Iroquois.
- Market Cap: $285.54 (M)
- Revenue LTM: $8.43 (M)
- Revenue LTM-1: $0.55(M)
- 1 Year Revenue Growth: 1429%
- YTD Price Change: 146.1%
Knight Therapeutics Inc. (TSE:GUD) – $9.60
Pharmaceuticals
Knight Therapeutics Inc is a Canada-based pharmaceutical company that is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO, PROBUPHINE, Advaxis Family of Products, Ember Family of Products, NeurAxon Family of Products, Antibe Family of Products, Blood Factor Products and VEWS Vascular Early Warning System.
- Market Cap: $1273.94 (M)
- Revenue LTM: $2.66 (M)
- Revenue LTM-1: $0.696 (M)
- 1 Year Revenue Growth: 282%
- YTD Price Change: 24.4%
Acerus Pharmaceuticals Corporation (TSE:ASP) – $0.20
Pharmaceuticals
Acerus Pharmaceuticals Corporation, formerly Trimel Pharmaceuticals Corporation, is a Canada-based pharmaceutical company engaged in the development, manufacture, marketing and distribution of products with a focus on men’s health, including urology, and women’s health, including hormone replacement therapy and female sexual dysfunction. The Company markets Estrace in Canada, which is an oral, plant-derived 17-beta estradiol therapy for the relief of symptoms of menopause.
- Market Cap: $41.51 (M)
- Revenue LTM: $42.28 (M)
- Revenue LTM-1: $12.44(M)
- 1 Year Revenue Growth: 240%
- YTD Price Change: 62.5%
